On the evening of March 24, yimaitong released the audited comprehensive annual results for the fiscal year ended December 31, 2021 (“fiscal year 2021”), which showed that the company achieved an operating revenue of RMB 284 million in fiscal year 2021, with a year-on-year increase of 33.2%, and the adjusted net profit of non Hong Kong Financial Reporting Standards was RMB 107 million, A year-on-year increase of 25.4% (non HKFRS profit: excluding non operating and one-time expenses, such as listing expenses, share based compensation expenses, one-time withholding income tax expenses and exchange differences, totaling RMB 60 million).
According to the data, the scale of yimaitong users increased steadily in 2021, from 3.5 million at the end of 2020 to 5.5 million at the end of 2021. Among them, the number of registered practitioners increased from 2.4 million at the end of 2020 to 3.1 million at the end of 2021, accounting for 58% to 75% of Chinese practitioners in the same period.
Tian Liping, chairman of yimaitong, said that in 2021, the company accelerated the expansion of the breadth of medical knowledge content of the platform to support clinical decision-making and drive user participation, resulting in a significant increase in user scale and user activity. The breadth of high-quality content helps Chinese doctors more efficiently perceive the latest trends of world medicine. Yimaitong content tool products “disease knowledge base”, “clinical guidelines”, “latest medical progress”, “medical video” and “drug information” have been greatly expanded, of which the increase of “clinical guidelines” is about 50%, and the increase of “medical videos” is about 193.4%, reaching 43000. At the same time, the pharmaceutical reform has prompted pharmaceutical enterprises to urgently seek the marketing scheme of digital chemistry. Based on the Internet learning behavior portrait of doctors and the clinical decision support system of doctors, yimaitong has successfully helped customers achieve the academic marketing efficiency and cost reduction goal of new special drugs and mature prescriptions affected by volume procurement.
